BioNTech SE Enters Global Co-Development Deal

TL;DR

BNTX inks global co-development deal, details TBD.

AI Summary

On June 2, 2025, BioNTech SE entered into a Global Co-Development and Commercialization Agreement with an unnamed partner. This agreement outlines the terms for co-developing and commercializing a specific product, though the details of the product and the partner are not disclosed in this filing.

Why It Matters

This agreement signifies BioNTech's strategic expansion into new co-development opportunities, potentially broadening its product pipeline and market reach.

Risk Assessment

Risk Level: medium — The lack of specific details regarding the partner and the product in the filing introduces uncertainty about the potential success and financial implications of the agreement.

Key Players & Entities

• BioNTech SE (company) — Registrant and party to the agreement
• June 2, 2025 (date) — Date the agreement was entered into

FAQ

Key Financial Figures

• $1.5 billion — nder the BMS Agreement, BMS will pay us $1.5 billion in an upfront payment and $2 billion to
• $2 billion — $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary pay
• $7.6 billion — n, we will be eligible to receive up to $7.6 billion in additional development, regulatory a

Filing Documents

• form6-kbmsagreement8sep2025.htm (6-K) — 28KB
• exhibit991bmsamendedandres.htm (EX-99.1) — 1421KB
• 0001776985-25-000057.txt ( ) — 1450KB

From the Filing

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On June 2, 2025, BioNTech SE (Nasdaq BNTX, " BioNTech ", " we " or " us ") entered into a Global Co-Development and Co-Commercialization Agreement (the " Original Agreement ") with Bristol-Myers Squibb Company (" BMS ") to jointly develop, manufacture and commercialize our investigational bispecific antibody BNT327 across numerous solid tumor types. We assigned our rights and obligations under the Original Agreement to BioNTech US Inc., pursuant to an Assignment and Assumption Agreement dated June 2, 2025 which was amended on August 15, 2025. In connection with the assignment, the parties also entered into a Parent Guarantee in favor of BMS dated June 2, 2025. The Original Agreement was amended and restated on August 15, 2025 to further define the performance-related rights and obligations of the collaboration (as so amended and restated, the " BMS Agreement "). As previously disclosed, under the BMS Agreement, BMS will pay us $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028. In addition, we will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones. The parties will equally share global profits and losses. The parties have agreed to use commercially reasonable efforts to jointly develop BNT327, as a monotherapy or in combination with other products, pursuant to a joint development plan (the " JDP "). Development costs will generally be shared equally provided, if a particular joint clinical trial involves BNT327 in combination with a proprietary or in-licensed asset of either party, cost sharing will be on an adjusted basis, subject to certain exceptions. Each party may propose new clinical trials for additional indications or combinations to the JDP. If the other party declines co-funding of a proposed new trial in the JDP, the proposing party may proceed independently at its own cost, under the oversight of the joint development committee, subject to certain reimbursement rights against the other party. The parties have also agreed to use commercially reasonable efforts to jointly commercialize BNT327 pursuant to a jointly developed global commercialization strategy and certain co-commercialization and market access plans. The parties will equally share any profits and losses from the commercialization of BNT327. A joint commercialization committee will coordinate and allocate commercial responsibilities, including the "lead" role with respect to specific activities, in an equitable manner to maximize the success of BNT327 and to maximize the efficiencies of the collaboration and avoid duplication of efforts as much as possible. Each party has the right to equally contribute (on a market-by-market basis) to all strategic commercial planning and execution, subject to certain exceptions. We will be solely responsible and will use commercially reasonable efforts for the global clinical supply of BNT327 initially before the completion of a manufacturing technology transfer from us to BMS (the " Manufacturing Transfer "). Following the completion of the Manufacturing Transfer, we will continue to be responsible and will use commercially reasonable efforts for the global clinical supply of BNT327, but the parties may agree for BMS to manufacture certain quantities of the clinical supply. Following the completion of the Manufacturing Transfer and BMS being otherwise ready to manufacture and supply at scale, BMS will be responsible for the commercial supply of BNT327, provided that we retain the right to contribute a certain percentage of global commercial supply. Each party has also granted to the other party certain co-exclusive licenses under its intellectual property (" IP "), including patents and know-how (including to each party's share of any future jointly owned IP under the BMS Agreement), to perform development and medical affairs activities with respect to, seek and obtain regulatory approvals of, and manufacture, commercialize and otherwise exploit BNT327. The parties have also agreed to a mutual right of first negotiation, effective

View Full Filing

View this 6-K filing on SEC EDGAR